Drug Discovery World features Dr. Michael Seiler as the author and he discusses immunodeficient models, advances in human immune system models, and immuno-oncology studies and applications:
"From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer.
Among those, spontaneous and genetically engineered immunodeficient strains can be administered in both primary human tumour tissue and cancer cell lines such that they grow to become one of the most widely used in vivo tools for target validation and efficacy."
"From inbred wild-type to more advanced genetically-engineered strains, mouse models enable researchers to gain important insights into the complex biological underpinnings of human cancer. Among those, spontaneous and genetically engineered immunodeficient strains can be administered in both primary human tumour tissue and cancer cell lines such that they grow to become one of the most widely used in vivo tools for target validation and efficacy."
Read the complete article at: DDW-Online.com